ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Condition: Non-Small Cell Lung Cancer
Sponsor: OSE Immunotherapeutics
Full Title
Protocol OSE2101C302: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
Study Treatment
OSE2101, a peptidic cancer vaccine, given in combination with chemotherapeutic agent docetaxel
Eligibility/Info
Participants must have a history of an advanced/metastatic non-small cell lung cancer that has progressed after at least 24 weeks of first line treatment with immunotherapy.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
